REVELATION BIOSCIENCES, INC.
Business
Revelation Biosciences is a clinical-stage biopharmaceutical company developing Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a TLR4 agonist designed to modulate inflammatory responses. The company is advancing two lead programs: GEM-AKI for acute kidney injury and GEM-CKD for chronic kidney disease, both supported by preclinical and clinical data. Revelation operates as a single operating entity focused on kidney disease indications and potential out-licensing opportunities in other therapeutic areas.
Summary from 10-K filed 2026-02-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 4 | 4 | 4 | 5 | 7 | |
| General and administrative | 5 | 4 | 5 | 5 | 5 | |
| Total operating expenses | 9 | 8 | 9 | 11 | 12 | |
| Loss from operations | −9 | −8 | −9 | −11 | −12 | |
| Change in fair value of warrant liability | 2,158 | 81,441 | 8 | 0 | 1 | |
| Other income (expense), net | 155,007 | −7 | 207,473 | 34,962 | −36,352 | |
| Total other income (expense), net | 157,165 | −7 | 9 | 34,962 | −36,352 | |
| Net loss | −9 | −15 | −120,254 | −11 | −12 | |
| Deemed dividends | −6 | — | — | — | — | |
| Net loss attributable to common stockholders | −15 | −15 | — | — | — | |
| Net loss per share, basic | −23.95 | −1,052 | −8.44 | −149.2 | −42.5 | |
| Net loss per share, diluted | −23.95 | −1,052 | −8.44 | −149.2 | −42.5 | |
| Weighted-average shares used to compute net loss per share, basic | 620,785 | 14,293 | 14,246 | 72,585 | 282,035 | |
| Weighted-average shares used to compute net loss per share, diluted | 620,785 | 14,293 | 14,246 | 72,585 | 282,035 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 11 | 6 | 12 | 5 | — | |
| Prepaid expenses and other current assets | 111,297 | 66,699 | 84,691 | 73,132 | — | |
| Total current assets | 11 | 7 | 12 | 5 | — | |
| Property and equipment, net | 18,067 | 56,332 | 65,084 | 90,133 | — | |
| Operating lease right-of-use asset | 722,288 | 0 | — | — | — | |
| Other assets | 30,941 | 0 | — | — | — | |
| Total assets | 12 | 7 | 12 | 6 | — | |
| Accounts payable | 577,501 | 783,621 | 1 | 554,205 | — | |
| Accrued expenses | 1 | 1 | 1 | 985,497 | 2 | |
| Operating lease liability | 23,013 | 0 | — | — | — | |
| Total current liabilities | 2 | 2 | 6 | 4 | — | |
| Operating lease liability, net of current portion | 723,771 | 0 | — | — | — | |
| Total liabilities | 3 | 2 | 6 | 4 | — | |
| Commitments and Contingencies (Note 4) | — | — | — | — | — | |
| Common Stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024 and 1,583,969 and 43,526 issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 1,584 | 44 | 16 | 77 | — | |
| Additional paid-in-capital | 58 | 45 | 32 | 26 | — | |
| Accumulated deficit | −49 | −41 | −25 | −25 | — | |
| Total stockholders' equity | 9 | 5 | 7 | 1 | — | |
| Total liabilities and stockholders' equity | 12 | 7 | 12 | 6 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation expense | 595,368 | 168,850 | 155,721 | 301,116 | 470,878 | |
| Depreciation expense | 27,058 | 27,923 | 25,049 | 25,048 | 16,782 | |
| Non-cash lease expense | 18,630 | — | 0 | 14,960 | 52,384 | |
| Loss on disposal of equipment | 11,207 | — | — | — | — | |
| Issuance of common stock for services | — | 25,000 | — | — | — | |
| Prepaid expenses and other current assets | −44,598 | 17,992 | −11,559 | 569,044 | −509,342 | |
| Deferred offering costs | — | 71,133 | 82,071 | −61,154 | — | |
| Other assets | −30,941 | — | — | — | — | |
| Accounts payable | −206,120 | −576,277 | 749,660 | −666,042 | −269,640 | |
| Accrued expenses | 269,756 | −3 | 161,963 | −592,987 | 1 | |
| Operating lease liability | 5,866 | — | 0 | −16,752 | −50,592 | |
| Net cash used in operating activities | −8 | −18 | −7 | −11 | −11 | |
| Purchase of property and equipment | — | −19,171 | — | — | −131,963 | |
| Net cash used in investing activities | — | −19,171 | — | — | −131,963 | |
| Net cash provided by financing activities | 12 | 13 | 14 | 15 | 8 | |
| Net increase (decrease) in cash and cash equivalents | 4 | −5 | 7 | 4 | −3 | |
| Deemed dividend for exercise price reductions of warrants | 6 | — | — | — | — | |
| Operating lease right-of-use asset exchanged for lease liability | 740,918 | — | — | — | 67,344 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is REVELATION BIOSCIENCES, INC.'s CIK number?
REVELATION BIOSCIENCES, INC.'s SEC CIK number is 0001810560 (1810560). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find REVELATION BIOSCIENCES, INC.'s SEC filings?
All of REVELATION BIOSCIENCES, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did REVELATION BIOSCIENCES, INC. last report earnings?
REVELATION BIOSCIENCES, INC. (REVB) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-212064). This is REVELATION BIOSCIENCES, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is REVELATION BIOSCIENCES, INC.'s most recent earnings 8-K?
REVELATION BIOSCIENCES, INC.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-212064. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View REVELATION BIOSCIENCES, INC.'s latest earnings 8-K →
Look up any company's CIK number →